Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
19 Agosto 2021 - 09:34AM
Business Wire
Study to be presented at the Society for
Neuro-Oncology Third Annual Conference on Brain Metastases, Aug.
19-20
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays and services, today announced that new data show
the company’s cerebrospinal fluid assay, CNSide™, detected tumor
cells and identified actionable mutations in lung cancer patients
with leptomeningeal carcinomatosis, allowing for targeted treatment
decisions that may improve outcomes and extend life expectancy. The
study will be presented as a poster at the Third Annual Conference
on Brain Metastases hosted by the Society for Neuro-Oncology (SNO),
being held virtually Aug. 19-20, 2021.
More than 198,000 patients are diagnosed with non-small cell
lung cancer (NSCLC) each year. An estimated 3-9% of those patients
will develop leptomeningeal carcinomatosis (LMC), a complication in
which the cancer spreads to the membranes surrounding the brain and
spinal cord. LMC is typically diagnosed through clinical
evaluation, imaging and cytology, which have limited sensitivity.
When left untreated, the average patient life expectancy is just
four to six weeks.
The retrospective study, conducted at the University of Utah
Huntsman Cancer Institute, used Biocept’s CNSide assay to detect
and analyze tumor cells in the cerebrospinal fluid of 15 unique
patients. Of the samples analyzed, CNSide detected tumor cells in
100% of samples with LMC, while cytology detected tumor cells in
just 40% of the samples. CNSide also identified actionable
biomarkers in tumor cells, which allowed oncologists to make
targeted treatment decisions that reduced debilitating symptoms and
extended patient lives by more than three years in some cases. The
study results suggest that CNSide is more sensitive than cytology,
and survival of patients with LMC can be prolonged if an actionable
target is identified and treated.
“LMC is a devastating diagnosis for patients and, quite often,
hospice is the only recommended course of action,” said Wallace
Akerley, M.D., University of Utah Huntsman Cancer Institute, and
lead study investigator. “However, we now have targeted therapies
that can improve and dramatically extend the lives of patients with
LMC who have a treatable mutation. This study shows that using
CNSide to interrogate the cerebrospinal fluid for actionable
mutations provides the information needed to determine the
appropriate treatment for patients with LMC. With the right
therapy, we have the ability to restore quality of life and extend
life expectancy for many patients.”
“Identifying actionable mutations is critical for treating
patients with LMC,” said Michael C. Dugan, M.D., Biocept’s Chief
Medical Officer and Medical Director. “CNSide has demonstrated the
ability to reliably detect and analyze tumor cells in the
cerebrospinal fluid that may not be found in blood or tissue
samples. The specific molecular targets identified in these tumor
cells can help guide a physician's choice of newer, more effective
therapies and inform the response to therapy in a way that can
really help these patients see an improvement of symptoms and live
significantly longer lives."
The study, titled “Beyond Cytology – A Single Institution
Experience Using CNSide™ for Diagnosing and Monitoring Treatment
Response in Non-Small Cell Lung Cancer Patients with Leptomeningeal
Carcinomatosis (LMC),” can be accessed here.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like “may,” "will," "designed,"
and "potential" or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements regarding the ability of CNSide to
identify actionable mutations in lung cancer patients with LMC that
allow for targeted treatment decisions that may improve outcomes
and extend life expectancy, the ability of CNSide cerebrospinal
fluid assay to diagnose cancer that has metastasized to the central
nervous system and the ability of Biocept’s molecular diagnostic
assays to provide physicians with clinically actionable information
to aid in the diagnosis, treatment and monitoring of patients with
cancer, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risks and uncertainties, including the risk
that our products and services may not perform as expected. These
and other risks are described in greater detail under the "Risk
Factors" heading of our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2021, as filed with the Securities and
Exchange Commission (SEC) on August 16, 2021. The effects of such
risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210819005178/en/
Biocept Contacts Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com,
310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024